About Us
Nanophysics & Beyond
Curadigm
The Management
Our Commitments
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Shareholders
Corporate Presentation
Financial Calendar
Regulated Information
Annual General Meetings
Shareholder Corner
Press Releases
Nanotalks
NBTXR3 Development
Head & Neck Cancer
R&D Day
Congresses
& Events
Our Expert Videos
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Scientific Clinical | Nanobiotix provides update on the global development of its lead product NBTXR3
Financial | Nanobiotix successfully completes approximately eur 27.2 million placement of new shares
31 October 2017
Scientific Clinical | Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting
13 November 2017
Scientific Clinical | Nanobiotix provides update on the global development of its lead product NBTXR3
Published by
adminvl
on
9 November 2017
No translations available for this page
